Who We Are

Delivering on our promise for patients

Founded in 1999 in Copenhagen, Denmark, we are a dual-listed, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.

We are led by an experienced international management team. Our proprietary product pipeline and next-generation antibody technologies are the result of our strong company culture and a deep passion for innovation. We are inspired by nature and the power of the immune system to transform cancer treatment.

Button

History

A history of accomplishments rooted in science

From our start in Copenhagen in 1999, our continued commitment to oncology has given us purpose and a drive to improve the lives of patients with cancer. We strive to achieve this goal by working together as one team and building on our world-class research in antibodies to expand our capabilities beyond the lab.

While we are proud of our past accomplishments for getting us to this point, we keep our eyes and minds focused on what’s next. Our history has been powered by a dedication to antibody-based therapeutics. It is this same spirit that will guide us into the future.

Scroll down to see some of our key accomplishments, milestones and moments.

  • 2020
    • Genmab announces very favorable topline results from phase 2 clinical trial of tisotumab vedotin in recurrent or metastatic cervical cancer
    • Genmab and AbbVie enter into broad oncology collaboration
    • Subcutaneous formulation of DARZALEX® (daratumumab) approved in Europe for adult patients with multiple myeloma in all currently approved daratumumab intravenous formulation indications
    • Subcutaneous formulation of daratumumab, DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) approved by U.S. FDA for certain multiple myeloma indications
    • First DuoBody® product candidate (amivantamab) awarded Breakthrough Therapy Designation by U.S. FDA
    • TEPEZZA® (teprotumumab) approved in U.S. for Thyroid Eye Disease
    • DARZALEX® (daratumumab) approved in Europe for use in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT)

    Read more +

  • 2019
    • DARZALEX® sales by Janssen approach USD ~3 billion in a calendar year
    • Genmab enters into a research collaboration and license agreement with CureVac AG for development of mRNA-based antibody therapeutics
    • DARZALEX® approved in Europe and in the U.S. for use in combination with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for ASCT
    • DARZALEX® approved in the U.S. in combination with bortezomib, thalidomide and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are eligible for ASCT
    • DARZALEX® approved in Japan in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma ineligible for ASCT
    • Genmab becomes a dual-listed company with shares traded on Nasdaq Copenhagen and Nasdaq Global Select Market in the U.S. in landmark IPO; wins LifeStars 2019 European IPO of the Year
    • Genmab signs agreement with Janssen for next-generation CD38 antibody, HexaBody®-CD38
    • Genmab celebrates its 20th anniversary

    Read more +

  • 2018
    • Genmab unveils its HexElect® platform
    • DARZALEX® approved in the U.S. and Europe for use in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for ASCT
    • Genmab enters strategic partnership with Immatics Biotechnologies GmbH to discover and develop next-generation bispecific cancer immunotherapies

    Read more +

  • 2017
    • Genmab wins Clinical Advance of the Year Award for the daratumumab CASTOR & POLLUX studies (together with Janssen) at the Scrip Awards 2017
    • DARZALEX® sales reach USD 1 billion in a calendar year
    • DARZALEX® approved in Japan for use in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma
    • Seattle Genetics exercises option to co-develop and co-commercialize tisotumab vedotin
    • DARZALEX® approved by the U.S. FDA for use in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor
    • DARZALEX® receives European marketing authorization for use in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy

    Read more +

  • 2016
    • Genmab wins award for Biotech Company of the Year at the Scrip Awards 2016
    • DARZALEX® approved by the U.S. FDA for use in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy
    • Genmab wins award for Company of the Year at the European Mediscience Awards 2016
    • DARZALEX® receives European conditional marketing authorization for heavily pre-treated or double refractory multiple myeloma
    • Arzerra® (ofatumumab) approved in the U.S. for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL)
    • Genmab wins award for Company of the Year at the BioCapital Europe conference 2016
    • Arzerra® approved in the U.S. in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed CLL

    Read more +

  • 2015
    • Rights to ofatumumab transferred from GlaxoSmithKline (GSK) to Novartis
    • DARZALEX® approved by the U.S. FDA for patients with multiple myeloma who have received at least three prior lines of therapy
    • Genmab enters commercial agreement with Novo Nordisk for DuoBody® technology
    • Genmab enters commercial DuoBody® technology agreement with BioNTech

    Read more +

  • 2014
    • Genmab enters into ADC collaboration with Seattle Genetics combining ADC technology with HuMax-AXL® (enapotamab vedotin)
    • Genmab raises DKK 998 million in an international private placement
    • Arzerra® in combination with chlorambucil approved by the U.S. FDA to treat previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate

    Read more +

  • 2013
    • Genmab wins Biotech Company of the Year at the Annual Scrip Awards
    • Ofatumumab receives Breakthrough Therapy Designation from the U.S. FDA
    • Teprotumumab begins development in thyroid eye disease
    • Daratumumab receives first Breakthrough Therapy Designation from the U.S. FDA
    • Genmab establishes sponsored Level 1 American Depositary Receipt (ADR) Program in the U.S.

    Read more +

  • 2012
    • Genmab unveils its HexaBody® platform
    • Genmab enters worldwide agreement with Janssen Biotech, Inc. for daratumumab
    • Genmab enters DuoBody® platform collaboration with Janssen

    Read more +

  • 2011
    • Arzerra® is honored with the Galien Prize in the Netherlands

    Read more +

  • 2010
    • Genmab enters collaboration with Lundbeck
    • Genmab implements its updated three-pronged corporate strategy
    • Genmab enters into collaboration with Seattle Genetics to combine ADC technology with HuMax®-TF (tisotumab vedotin)
    • Genmab and GSK amend the ofatumumab collaboration agreement
    • Jan van de Winkel becomes CEO
    • The DuoBody® bispecific antibody technology platform is introduced

    Read more +

  • 2009
    • Arzerra® is launched by GSK in the U.S.
    • First-ever Biologics License Application for a Genmab antibody is filed for ofatumumab in CLL with GSK

    Read more +

  • 2008
    • Genmab and GSK report positive results from first Phase 3 study of ofatumumab in CLL

    Read more +

  • 2007
    • Development of ofatumumab in multiple sclerosis begins
    • Genmab wins the 2007 Scrip Biotech Company of the Year award

    Read more +

  • 2006
    • Genmab and GSK sign a co-development and commercialization agreement for ofatumumab
    • Genmab raises DKK 845 million in an international private placement

    Read more +

  • 2005
    • Daratumumab selected as CD38 antibody candidate
    • Genmab wins the 2004 James D. Helix Award for Best International Biotech Company

    Read more +

  • 2004
    • Genmab raises DKK 478 million in an international private placement
    • Genmab receives the James D. Watson Helix Award for Outstanding Performance by an International Biotechnology Company

    Read more +

  • 2003
    • Human antibodies generated to CD38

    Read more +

  • 2002
    • Genmab announces the ofatumumab program

    Read more +

  • 2001
    • Genmab enters its first major partnership, an antibody development collaboration with Roche

    Read more +

  • 2000
    • Genmab IPO in Copenhagen and Frankfurt raises DKK 1.56 billion, a European biotech record

    Read more +

  • 1999
    • Genmab founded in Copenhagen, Denmark

    Read more +

Load additional years

  • Turning insights into medicine

    See the results of innovation that is rooted in science

    Explore the pipeline

  • News, events and more

    Get the latest stock information and news about Genmab

    Learn more

  • Paving the way

    Get to know our senior leadership

    Meet our team

You are now leaving Genmab.com to go to our collaborator’s website. If you continue, we encourage you to read the website’s privacy and cookie policy.